Stemedica Reports Positive Results from Phase IIa Clinical Trial Using IV Administration of Mesenchymal Stem Cells for Ischemic Stroke

by stemedica admin | Oct 30, 2019 | Clinical Trials

San Francisco, CA – CONGRESS OF NEUROLOGICAL SURGEONS October 19, 2019 – October 23, 2019 – Study sponsor Stemedica Cell Technologies, Inc., a global biotechnology company that uses cGMP manufactured, ischemia-tolerant (itMSCs), bone marrow derived, allogeneic...

Positive Study Results of Phase IIa Clinical Trial Using Intravenous Administration of Mesenchymal Stem Cells for Ischemic Stroke Published in Peer-Reviewed Stroke Journal

by stemedica admin | Sep 30, 2019 | Clinical Trials

Study Sponsored by Stemedica Cell Technologies, Inc. SAN DIEGO, Calif. – (September 30, 2019)  – Results from a study sponsored by Stemedica Cell Technologies, Inc., a global biotechnology company that uses allogeneic stem cells for ischemic conditions, form the basis...

Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke

by stemedica admin | Sep 13, 2019 | Clinical Trials, Publications

Abstract Background and Purpose Stroke is a leading cause of long-term disability. Limited treatment options exist for patients with chronic stroke and substantial functional deficits. The current study examined safety and preliminary efficacy estimates of intravenous...

Stemedica Cell Technologies Reports Positive Data in Phase I/IIa Study of Allogeneic Stem Cells for Ischemic Stroke

by stemedica admin | Jan 7, 2019 | Clinical Trials

Stemedica Cell Technologies Reports Positive Data in Phase I/IIa Study of Allogeneic Stem Cells for Ischemic Stroke – itMSCs were safe and well tolerated in the study – – Results of the study are supportive of advancing clinical program –  ...

New Stem Cell Therapy May Transform Heart Failure Treatment

by stemedica admin | Apr 18, 2018 | Clinical Trials, Publications, Subsidiaries

Washington, D.C., April 18, 2018 – Clinical trial planning is underway at MedStar Heart & Vascular Institute to determine whether a novel stem cell therapy will improve heart function for patients with heart failure. MedStar Heart, in partnership with CardioCell,...